OBJECTIVES: To describe antiretroviral therapy (ART) use and clinical status, at start of and during pregnancy, for HIV-positive women receiving ART at conception, including the proportion conceiving on drugs (efavirenz and didanosine) not recommended for use in early pregnancy. METHODS: Women with a pregnancy resulting in a live-birth after 1995 (n = 1537) were identified in an observational cohort of patients receiving HIV care at 12 clinics in the UK by matching records with national pregnancy data. Treatment and clinical data were analysed for 375 women conceiving on ART, including logistic regression to identify factors associated with changing regimen during pregnancy. RESULTS: Of the 375 women on ART, 39 (10%) conceived on dual therapy, 306 (82%) on triple therapy and 30 (8%) on more than three drugs. In total, 116 (31%) women conceived on a regimen containing efavirenz or didanosine (69 efavirenz, 54 didanosine, seven both). Overall, 38% (143) changed regimen during pregnancy, of whom 44% (n = 51) had a detectable viral load around that time. Detectable viral load was associated with increased risk of regimen change [adjusted odds ratio 2.97, 95% confidence interval (CI) (1.70-5.19)], while women on efavirenz at conception were three times more likely to switch than women on other drugs [3.40, (1.84-6.25)]. Regimen switching was also associated with year at conception [0.89, (0.83-0.96)]. CONCLUSION: These findings reinforce the need for careful consideration of ART use among women planning or likely to have a pregnancy in order to reduce viral load before pregnancy and avoid drugs not recommended for early antenatal use.
OBJECTIVES: To describe antiretroviral therapy (ART) use and clinical status, at start of and during pregnancy, for HIV-positive women receiving ART at conception, including the proportion conceiving on drugs (efavirenz and didanosine) not recommended for use in early pregnancy. METHODS: Women with a pregnancy resulting in a live-birth after 1995 (n = 1537) were identified in an observational cohort of patients receiving HIV care at 12 clinics in the UK by matching records with national pregnancy data. Treatment and clinical data were analysed for 375 women conceiving on ART, including logistic regression to identify factors associated with changing regimen during pregnancy. RESULTS: Of the 375 women on ART, 39 (10%) conceived on dual therapy, 306 (82%) on triple therapy and 30 (8%) on more than three drugs. In total, 116 (31%) women conceived on a regimen containing efavirenz or didanosine (69 efavirenz, 54 didanosine, seven both). Overall, 38% (143) changed regimen during pregnancy, of whom 44% (n = 51) had a detectable viral load around that time. Detectable viral load was associated with increased risk of regimen change [adjusted odds ratio 2.97, 95% confidence interval (CI) (1.70-5.19)], while women on efavirenz at conception were three times more likely to switch than women on other drugs [3.40, (1.84-6.25)]. Regimen switching was also associated with year at conception [0.89, (0.83-0.96)]. CONCLUSION: These findings reinforce the need for careful consideration of ART use among women planning or likely to have a pregnancy in order to reduce viral load before pregnancy and avoid drugs not recommended for early antenatal use.
Authors: B G Gazzard; Jane Anderson; Abdel Babiker; Marta Boffito; Gary Brook; Gary Brough; Duncan Churchill; Ben Cromarty; Satyajit Das; Martin Fisher; Andrew Freedman; Anna Maria Geretti; Margaret Johnson; Saye Khoo; Clifford Leen; Devaki Nair; Barry Peters; Andrew Phillips; Deenan Pillay; Anton Pozniak; John Walsh; Ed Wilkins; Ian Williams; Matthew Williams; Mike Youle Journal: HIV Med Date: 2008-10 Impact factor: 3.180
Authors: H E Hsu; C E Rydzak; K L Cotich; B Wang; P E Sax; E Losina; K A Freedberg; S J Goldie; Z Lu; R P Walensky Journal: HIV Med Date: 2011-02 Impact factor: 3.180
Authors: Claire L Townsend; Mario Cortina-Borja; Catherine S Peckham; Annemiek de Ruiter; Hermione Lyall; Pat A Tookey Journal: AIDS Date: 2008-05-11 Impact factor: 4.177
Authors: Arlene D Bardeguez; Jane C Lindsey; Maureen Shannon; Ruth E Tuomala; Susan E Cohn; Elizabeth Smith; Alice Stek; Shelly Buschur; Amanda Cotter; Linda Bettica; Jennifer S Read Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: C A Mellins; C Chu; K Malee; S Allison; R Smith; L Harris; A Higgins; C Zorrilla; S Landesman; L Serchuck; P Larussa Journal: AIDS Care Date: 2008-09
Authors: Allan W Taylor; Steven R Nesheim; Xinjian Zhang; Ruiguang Song; Lauren F FitzHarris; Margaret A Lampe; Paul J Weidle; Patricia Sweeney Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Susie Huntington; Claire Thorne; Marie-Louise Newell; Jane Anderson; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline Sabin Journal: AIDS Date: 2015-04-24 Impact factor: 4.177
Authors: Susie E Huntington; Claire Thorne; Loveleen K Bansi; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Susie E Huntington; Loveleen K Bansi; Claire Thorne; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin Journal: BMC Med Res Methodol Date: 2012-07-28 Impact factor: 4.615